Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celsion CEO Michael Tardugno - An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

Tardugno speaks with the DAILY about the regulatory timeline and commercialization plans for ThermoDox, including plans to market the heat-activated liposomal-delivery doxorubicin in Asia.

You may also be interested in...



Celsion CEO Michael Tardugno – An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Tardugno speaks with the DAILY about his company’s transition from a device firm to an oncologic development company and about its proprietary technology.

Bayer/Onyx’s Nexavar Gets Liver Cancer Indication

Sorafenib becomes first systemic drug therapy approved for unresectable HCC.

China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel